CXCL13 concentrations during remission remains unclear, and the correlation between serum CXCL13 levels and the use of immunosuppressive therapy (azathioprine, steroids), the first‐line treatment of NMO during remission, has not been studied. Here, CXCL13 is linked to neuromyelitis optica.